长风药业(02652)预计2025年度经调整净利润约3000万元至3500万元，业务运营稳健，创新研发持续推进

智通财经

Yesterday

智通财经APP讯，长风药业(02652)发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得(i)收入介于人民币4.10亿元至4.50亿元;(ii)根据国际财务报告准则(IFRS)会计准则，股东应占溢利介于人民币200万元至300万元;(iii)经调整净利润(非国际财务报告准则指标)为介于人民币3000万元至3500万元。

自上市以来，集团已取得若干创新药申报关键进展等多项里程碑，以及完成国家主要集采产品的医疗机构品牌报量工作，以应对市场挑战并推动可持续增长：(a)布地奈德鼻喷雾剂的上市许可申请，以及ICF004与ICF001的新药临床试验申请，均已获中国国家药品监督管理局受理;此外，奥洛他定莫米松鼻喷雾剂的临床试验申请亦已获批，强化了集团在呼吸道及鼻腔护理领域的产品阵容;(b)根据国家VBP更新计划，针对CF017(吸入用布地奈德混悬液)在医疗机构的品牌报量工作已完成，医院涵盖范围已扩大至全国，且采购周期将延续至2028年底;(c)公司已获纳入恒生综合指数及沪港通与深港通下的港股通合资格证券名单，预期将提升H股的交易流动性;(d)公司已根据2025年12月获授的一般授权，进行了若干H股回购。公司或会视市场情况及资金安排，在遵守上市规则及适用法规的前提下，考虑进一步回购H股。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2621059758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621059758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621059758?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-21 00:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621059758","market":"sh","top_or_hot":-1,"title":"长风药业(02652)预计2025年度经调整净利润约3000万元至3500万元，业务运营稳健，创新研发持续推进","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02652\">长风药业</a>(02652)发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得(i)收入介于人民币4.10亿元至4.50亿元;(ii)根据国际财务报告准则(IFRS)会计准则，股东应占溢利介于人民币200万元至300万元;(iii)经调整净利润(非国际财务报告准则指标)为介于人民币3000万元至3500万元。</p><p>自上市以来，集团已取得若干创新药申报关键进展等多项里程碑，以及完成国家主要集采产品的医疗机构品牌报量工作，以应对市场挑战并推动可持续增长：(a)布地奈德鼻喷雾剂的上市许可申请，以及ICF004与ICF001的新药临床试验申请，均已获中国国家药品监督管理局受理;此外，奥洛他定莫米松鼻喷雾剂的临床试验申请亦已获批，强化了集团在呼吸道及鼻腔护理领域的产品阵容;(b)根据国家VBP更新计划，针对CF017(吸入用布地奈德混悬液)在医疗机构的品牌报量工作已完成，医院涵盖范围已扩大至全国，且采购周期将延续至2028年底;(c)公司已获纳入恒生综合指数及沪港通与深港通下的港股<a href=\"https://laohu8.com/S/300491\">通合</a>资格证券名单，预期将提升H股的交易流动性;(d)公司已根据2025年12月获授的一般授权，进行了若干H股回购。公司或会视市场情况及资金安排，在遵守上市规则及适用法规的前提下，考虑进一步回购H股。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长风药业(02652)预计2025年度经调整净利润约3000万元至3500万元，业务运营稳健，创新研发持续推进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长风药业(02652)预计2025年度经调整净利润约3000万元至3500万元，业务运营稳健，创新研发持续推进\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-21 00:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1416996.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，长风药业(02652)发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得(i)收入介于人民币4.10亿元至4.50亿元;(ii)根据国际财务报告准则(IFRS)会计准则，股东应占溢利介于人民币200万元至300万元;(iii)经调整净利润(非国际财务报告准则指标)为介于人民币3000万元至3500万元。自上市以来，集团已取得若干创新药申报关键进展等多项...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416996.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1416996.html","article_id":"2621059758","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621059758","pubTimestamp":1774024786,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，长风药业 发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得收入介于人民币4.10亿元至4.50亿元;根据国际财务报告准则会计准则，股东应占溢利介于人民币200万元至300万元;经调整净利润为介于人民币3000万元至3500万元。公司或会视市场情况及资金安排，在遵守上市规则及适用法规的前提下，考虑进一步回购H股。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"02652":"长风药业"},"translate_title":"Changfeng Pharmaceutical (02652) expects an adjusted net profit of approximately 30 million yuan to 35 million yuan in 2025, with steady business operations and continuous advancement in innovative research and development","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1.5},"content_text":"智通财经APP讯，长风药业(02652)发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得(i)收入介于人民币4.10亿元至4.50亿元;(ii)根据国际财务报告准则(IFRS)会计准则，股东应占溢利介于人民币200万元至300万元;(iii)经调整净利润(非国际财务报告准则指标)为介于人民币3000万元至3500万元。自上市以来，集团已取得若干创新药申报关键进展等多项里程碑，以及完成国家主要集采产品的医疗机构品牌报量工作，以应对市场挑战并推动可持续增长：(a)布地奈德鼻喷雾剂的上市许可申请，以及ICF004与ICF001的新药临床试验申请，均已获中国国家药品监督管理局受理;此外，奥洛他定莫米松鼻喷雾剂的临床试验申请亦已获批，强化了集团在呼吸道及鼻腔护理领域的产品阵容;(b)根据国家VBP更新计划，针对CF017(吸入用布地奈德混悬液)在医疗机构的品牌报量工作已完成，医院涵盖范围已扩大至全国，且采购周期将延续至2028年底;(c)公司已获纳入恒生综合指数及沪港通与深港通下的港股通合资格证券名单，预期将提升H股的交易流动性;(d)公司已根据2025年12月获授的一般授权，进行了若干H股回购。公司或会视市场情况及资金安排，在遵守上市规则及适用法规的前提下，考虑进一步回购H股。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}